Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells

Cancer Investigation

Volumn 28, Issue 6, 2010, Pages 623-628

  Baran, Yusuf ^a   Oztekin, Coskun ^b   Bassoy, Esen Yonca ^a  

^a IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Apoptosis; BCR ABL; Chronic myeloid leukemia; Fludarabine; Imatinib

Indexed keywords

CASPASE 3; FLUDARABINE; IMATINIB;

APOPTOSIS; ARTICLE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL DEATH; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; PIPERAZINES; PYRIMIDINES; VIDARABINE;

EID: 77953182889     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357901003631056     Document Type: Article

References (25)

1. Ramirez, P.; DiPersio, J.F. Therapy options in imatinib failures. Oncologist 2008, 13, 424-434.
2. Baran, Y.; Salas, A.; Senkal, C.E.; Gunduz, U.; Bielawski, J.; Obeid, L.M.; Ogretmen, B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007, 282, 10922-10934.
3. Cang, S.; Liu, D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008, 1, 15.
4. Steinberg, M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosomepositive acute lymphoblastic leukemia. Clin Ther 2007, 29, 2289-2308.
5. Sallmyr, A.; Fan, J.; Rassool, F.V. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008, 270, 1-9.
6. Koca, E.; Haznedaroglu, I.C. Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turkish J Hematology 2005, 22(4), 161-172.
7. Jakubowska, J.; Wasowska-Lukawska, M.; Czyz, M. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis. Eur J Pharmacol 2008, 596, 41-49.
8. Henkes, M.; Van Der Kuip, H.; Aulitzky, W.E. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag 2008, 4, 163-187.
9. Ding, X.; Herzlich, A.A.; Bishop, R.; Tuo, J.; Chan, C.C. Ocular toxicity of fludarabine: a purine analog. Expert Rev Ophthalmol 2008, 3, 97-109.
10. Nitsche, M.; Christiansen, H.; Hermann, R.M.; Lucke, E.M.; Peters, K.; Rave-Frank, M.; Schmidberger, H.; Pradier, O. The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro. Int J Radiat Biol 2008, 84, 643-657.
11. Clavio, M.; Venturino, C.; Pierri, I.; Garrone, A.; Miglino, M.; Canepa, L.; Balleari, E.; Balocco, M.; Michelis, G.L.; Ballerini, F.; Gobbi, M. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 2004, 83, 696-703.
12. Harned, T.M.; Gaynon, P.S. Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag 2008, 4, 327-336.
13. Rosato, R.R.; Almenara, J.A.; Maggio, S.C.; Coe, S.; Atadja, P.; Dent, P.; Grant, S. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol. Cancer Ther 2008, 7, 3285-3297.
14. Komarova, N.L.; Wodarz, D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci 2005, 102, 9714-9719. (Pubitemid 40981746)
15. Baran, Y.; Ural, A.U.; Gunduz, U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007, 12, 497-503.
16. Soverini, S.; Iacobucci, I.; Baccarani, M.; Martinelli, G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. Haematologica 2007, 92, 437-439.
17. Robak, T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev 2007, 33, 710-728. (Pubitemid 350089291)
18. Cortes, J.; Jabbour, E.; Daley, G.Q.; O'Brien, S.; Verstovsek, S.; Ferrajoli, A.; Koller, C.; Zhu, Y.; Statkevich, P.; Kantarjian, H. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007, 110, 1295-1302. (Pubitemid 47435601)
19. Rai, K.R.; Peterson, B.L.; Appelbaum, F.R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threatte, G.A.; Larson, R.A.; Cheson, B.D.; Schiffer, C.A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343, 1750-1757.
20. Tournilhac, O.; Cazin, B.; Leprètre, S.; Diviné, M.; Maloum, K.; Grosbois, B.; Feugier, P.; Maloisel, F.; Villard, F.; Villemagne, B.; Bastit, D.; Belhadj, K.; Azar, N.; Michallet, M.; Manhès, G.; Travade, P. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004, 103, 363-365.
21. Fruehauf, S.; Topaly, J.; Buss, E.C.; Fischer, T.; Ottmann, O.G.; Emmerich, B.; Müller, M.C.; Schuld, P.; Balleisen, L.; Hehlmann, R.; Ho, A.D.; Hochhaus, A. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 2007, 109, 1543-1549.
22. Tsimberidou, A.M.; Estey, E.; Cortes, J.E.; Garcia-Manero, G.; Faderl, S.; Verstovsek, S.; Thomas, D.A.; Ferrajoli, A.; Keating, M.J.; O'Brien, S.; Kantarjian, H.M.; Giles, F.J. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003, 52, 449-452.
23. Shanafelt, T.D.; Lee, Y.K.; Bone, N.D.; Strege, A.K.; Narayanan, V.L.; Sausville, E.A.; Geyer, S.M.; Kaufmann, S.H.; Kay, N.E. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. Blood 2005, 105, 2099-2106.
24. Moufarij, M.A.; Sampath, D.; Keating, M.J.; Plunkett, W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006, 108, 4187-4193
25. Korycka, A.; Robak, T. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro. Leuk Lymphoma 2003, 44, 1549-1555.